Positive Reinforcement for Viruses  by Vigant, Frederic et al.
Chemistry & Biology
PreviewsPositive Reinforcement for VirusesFrederic Vigant,1 Michael Jung,2 and Benhur Lee1,3,4,*
1Department of Microbiology, Immunology, and Molecular Genetics
2Department of Chemistry and Biochemistry
3Department of Pathology and Laboratory Medicine
4UCLA AIDS Institute
University of California, Los Angeles, Los Angeles, CA 90095, USA
*Correspondence: bleebhl@ucla.edu
DOI 10.1016/j.chembiol.2010.10.002
Virus-cell membrane fusion requires a critical transition from positive to negative membrane curvature.
St. Vincent et al. (2010), in PNAS, designed a class of antivirals that targets this transition. These rigid
amphipathic fusion inhibitors are active against an array of enveloped viruses.Viruses are either membrane-enveloped
or not. Althoughviralmembranesoriginate
from cellular membranes, they can be
biochemically and physically distinct.Figure 1. Schematic Cross-Section
View of Viral-Cell Membrane Fusion
(A) The viral membrane (in blue) has a
strong positive curvature (J > 0) and the
cellular membrane (in yellow) looks virtually
flat in comparison (J 0). After juxtaposi-
tion of membranes and triggering of the
fusion proteins (not depicted), (B) the outer
leaflets of both membranes start fusing
and a stalk, with a highly negative curvature
(J < 0) is formed. This step, called hemifu-
sion, allows for lipid mixing that involves
only the outer leaflets of the viral and
cellular membrane bilayer (in green).
(C) The final step is the pore formation and
enlargement, which will ultimately lead to
complete bilayer and content mixing
(delivery of viral content in the cell’s
cytoplasm).Their relative lipid, cholesterol, and
protein content can be different
from a healthy cell’s membrane,
and the proper balance between
these components are critical for
maintaining the virus’s size and
shape and ultimately its ability to
fuse with cellular membranes.
While the specific mechanics of
fusion may differ between the
classes of viral fusion proteins,
some general features are common
to this process (Harrison, 2008).
Viral membranes have a high posi-
tive curvature relative to the host
cell membrane. After attachment/
binding of the viral particle and
triggering of the fusion protein,
which requires specific interactions
between viral envelope glycopro-
teins and cognate receptors, virus-
cell fusionproceeds throughahemi-
fusion intermediate comprising of
a lipid stalk where the outer leaflet
of the viral membrane phospholipid
bilayer is mixed with its counterpart
on the host cell membrane (Cherno-
mordik et al., 2006) (Figure 1). This
step of lipid mixing between viral
and cellular membranes is charac-
terized by a transition from positive
to negative curvature. The unfavor-
able energetics of this transition are
overcome by the energy released
from receptor-induced conforma-
tional changes in the viral envelope
glycoproteins and cellular mem-
brane destabilization mediated by
the viral fusion proteins (Harrison,2008). Complete fusion (bilayer lipid mix-
ing) and pore formation/enlargement
ultimately allows the virus to deliver its
content inside the target cell, but this finalChemistry & Biology 17, October 29, 2010 ªstep requires overcoming another ener-
getic hurdle (Chernomordik et al., 2006).
Based on the biophysics of virus-cell
membrane fusion, St. Vincent et al.2010(2010) designed and evaluated a
class of potentially broad-spectrum
antivirals, termed rigid amphipathic
fusion inhibitors (RAFIs), that can
interfere with the positive to nega-
tive curvature transitions central
to virus-cell fusion (Figure 1). It
is known that ‘‘inverted-cone’’-
shaped molecules (e.g., lysophos-
pholipids) that induce a positive
curvature in membranes are able
to inhibit viral- and cell-cell fusion.
However, these lipid-based mole-
cules are often cytotoxic or quickly
degraded. Nevertheless, agents
that promote the positive curvature
of a viral membrane (Figure 2) or
otherwise increase the energy
barrier required for positive to
negative curvature transitions re-
main appealing as a broad-spec-
trum antiviral concept. The studyElsevier Ltd All rights reserved 1049
Figure 2. Schematic Cross-Section View of a Viral
Envelope
(A) The viral membrane, composed of different lipids (in blue),
proteins (e.g., transmembrane envelope glycoprotein in black),
and cholesterol (in yellow) has a strong positive curvature
(J > 0).
(B) The addition of ‘‘inverted-cone’’-shaped RAFIs (in red)
increases the curvature (J > 0) of the viral membrane by specif-
ically inserting into the outer leaflet. RAFI-treated viruses are no
longer able to fuse with cellular membranes because the
energy required to form a stalk (Figure 1B) is now too high.
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this concept. The synthetic RAFIs
have an ‘‘inverted cone’’ shape
with the polar hydrophilic end larger
in diameter than the hydrophobic
end that inserts into the membrane
(Figure 2). Active RAFIs specifically
inhibit viral fusion with a mean IC50
of 50 nM, without overt cytotox-
icity (selectivity index > 100 for
most of the active ones). Impor-
tantly, RAFIs do not act as deter-
gents: treated viruses (HSV-1)
remain intact and are still able to
attach to target cells via their
cognate receptors. However, con-
tent- and lipid-mixing experiments
showed that RAFI-treated viruses
do not even progress to the hemifu-
sion stage (Figure 1). The RAFIs
specifically target membranes and
are active against different unre-
lated enveloped viruses (HSV-1,
HSV-2, HCV, VSV, and Sindbis
virus), albeit with different IC50s,
but not nonenveloped viruses
(Adenovirus and Poliovirus). Finally,
RAFIs disfavor the formation of
negatively curved hexagonal phase
of dielaidoylphosphatidylethanol-
amine (DEPE) structures. In toto,
the evidence is suggestive that
RAFIs inhibit enveloped viral entry
by acting on viral membranes andinhibiting, at least in part, the positive to
negative curvature transition that is crit-
ical for productive membrane fusion
(Figure 1).
The provocative studies by St. Vincent
et al. (2010) bring to mind the recent study
byWolf et al. (2010) that describes a series
of chemically unrelated compounds (repre-
sented by LJ001) with remarkably similar
properties. It remains to be determined if
LJ001 also acts in a mechanistically similar
fashion. However, a few differences can be
noted. As opposed to the simple benzene
group in the hydrophobic tail of LJ001, the
hydrophobic group, perylene, present in
effective RAFIs has a structure closely
related to hypocrellin A, a well-known
photosensitizer with antiviral and antineo-
plastic activities belonging to the family of
quinones (Krishnamoorthy et al., 2005).
Hydrophobic photosensitizers (such as
hypocrellin A) insert into membranes and
upon photoactivation (activation by light)
produce a reactive oxygen species (ROS)
that may be damaging to membrane1050 Chemistry & Biology 17, October 29, 20components. Itmaybe interesting to deter-
mine if this additional mechanism contrib-
utes to RAFIs’ antiviral activity. It seems
unlikely that just the lipid-binding activity
alone can account for the nanomolar
activity of RAFIs, given the vast excess of
cellular membrane components in mixed
virus-cell cultures. For that matter, it is
curious that RAFIs were not tested for their
ability to inhibitcell-cell fusion, aseven lyso-
phospholipids have been shown to inhibit
syncytia formation (Chernomordik et al.,
1995). Finally, as in the Wolf et al. (2010)
study, whether the concept of a broad-
spectrum therapeutic that targets the viral
lipid membrane can be translated into
in vivo efficacy remains to be determined.
The impressive antiviral activity of these
RAFIs broadens the chemotypes that may
be developed as potential broad-spec-
trum antivirals. Broad-spectrum antivirals
that target viral membranes have been
reported, although mechanistic studies
have not been as exhaustive. Docosanol
(Abreva), a long-chain saturated alcohol,10 ª2010 Elsevier Ltd All rights reservedseems to target viral membranes
and inhibits a variety of enveloped
viruses (Katz et al., 1994; Marcelletti
et al., 1996), although it is unclear
why the compound would still be
active when pre-incubated with
cells alone. Nevertheless, docosa-
nol has been developed as a topical
microbicide for treating herpes cold
sores. Cosalane also shows activity
against some enveloped viruses
(e.g., HIV and HSV), although it
seems to have unfavorable bioavail-
ability and pharmacokinetic proper-
ties that may limit its in vivo utility
(Zhan et al., 2010). More recently,
Bavituximab, a monoclonal anti-
body against phosphatidylserine,
has shown in vitro and in vivo activity
against multiple viruses (Soares
et al., 2008), although it is not yet
clear howgeneralizable this strategy
is; what is the spectrum of viruses
that externalize phosphatidylserine?
Nevertheless, our increasing under-
standing of the virus-cell fusion
process suggests that physical and
physiological differences that exist
between viral and cellular mem-
branes may be exploited for the
development of antiviral therapeu-
tics. A particularly appealing notion
that underlies this antiviral concept
is that viral membrane-targetingagents would necessarily limit the devel-
opment of resistance, as it is not even
conceptually clear how such resistance
may develop. Thus, targeting viral
membranes represents an exciting new
paradigm to explore regarding the devel-
opment of broad-spectrum antivirals.REFERENCES
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